Emcure Pharmaceuticals Ltd Q1 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/lzkoyznstrplk4i0b5om6md4.pdf

Key Takeaways


Domestic Business: Therapies, Portfolio Moves & New Bets

Satish Mehta: "With Amaryl coming to the fold, our position in the diabetics segment, metabolics will significantly strengthen and that will also help us when we go for semaglutide as and when we get to LOE."

International Business: The Growth Engine

Satish Mehta: "I want to highlight that your company is predominantly insulated from US market with our exposure to US being less than 3%."

Pipeline: The Binary Catalysts

Satish Mehta: "I take pride in telling everyone that as far as my company is concerned, it is in the forefront in launching new products and we're giving new products to the industry."

Margins & Capital Allocation


Organization & Leadership

Satish Mehta: "This is the first year of our 5-year vision to take Emcure into the next orbit."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic growthGrow above industryFY26
Volume growth4–5%FY26
EBITDA margin expansion150 bps total (100 bps opex + 50 bps gross margin)FY26
Emerging markets growthHigh teens to 20%FY26
Canada growthMid-teensSustainable, ongoing
Gross debt reductionApproach close to zero, barring M&AEnd of FY26
Operating margin target23–24% (from ~20% now)Over 4–5 years
Amphotericin B full volume effectMax volumes across geographiesNext 12 months
Amphotericin B near-term revenueEurope/UK/US approvals and supply4–6 months
Semaglutide Canada filingSubmissionEnd of FY26
Wet AMD clinical trial completionTrial complete, dossier to CDSCOEnd of September 2025
Asparaginase or wet AMD approvalAt least one approval expectedFY26
Derma and Consumer Wellness contribution1–2% additional domestic growthFY26
Tenecteplase dominanceVery dominant product18–24 months
r-Asparaginase and Bevacizumab ramp-upSignificant ramp-up across 4 products18–24 months

Key Metrics

MetricQ1 FY26
Revenue from operations₹2,101 cr, +15.7% YoY
Domestic revenue₹995 cr, +9.4% YoY
International revenue₹1,106 cr, +22% YoY
Emerging markets revenue₹360 cr, +42% YoY
Canada revenue₹342 cr, +16.4% YoY
Europe revenue₹403 cr, +12.8% YoY
Gross margin61.8%, vs 62.4% in Q1 FY25 and 57.8% in Q4 FY25
EBITDA₹404 cr, +20.1% YoY
EBITDA margin19.2%, vs 18.5% in Q1 FY25 and 18.4% in Q4 FY25
Profit after tax₹215 cr, +41% YoY, highest quarterly profit
Effective tax rate26%
Gross debt~₹700 cr
Cash and cash equivalents₹200 cr as of June 30, 2025, including investments
US exposureLess than 3% of total business
India volume growth~4%, with price growth ~4% and new launches ~1-2%
Domestic growth ex-Orofer FCM~10.5%, Orofer FCM contributed ~1% drag
ARV share of emerging markets~50%
Sanofi diabetes portfolio~₹200 cr annualized, ~8 months contribution expected in FY26
EBITDA margin expansion guidance for FY26150 bps total, 100 bps from opex and 50 bps from gross margin improvement
Margin improvement target over 4-5 years300-400 bps expansion from current levels
Annual capex guidance~₹350 cr, split ~₹150 cr repair/maintenance and ~₹200 cr capacity/product-specific
Emerging markets growth guidance for FY26High teens to 20%